Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flamel Technologies S.A. FLML

Healthcare Biotechnology
"Flamel Technologies SA is a specialty pharmaceutical company engaged in drug delivery and formulation development to create safer and more efficacious pharmaceutical products to address unmet medical needs and/or reduce overall healthcare costs."

Recent & Breaking News (NDAQ:FLML)

Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions

Accesswire March 28, 2016

Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results

Marketwired March 10, 2016

Flamel Technologies to Present at the 28th Annual ROTH Conference

Marketwired March 8, 2016

Flamel Technologies to Report Fourth Quarter and Full Year 2015 Results

Marketwired March 7, 2016

Flamel Technologies to Present at RBC Capital Markets' 2016 Global Healthcare Conference

Marketwired February 11, 2016

Flamel Technologies Acquires FSC Pediatrics

Marketwired February 8, 2016

Flamel Technologies Provides Update on Corporate Progress

Marketwired January 8, 2016

Flamel Technologies Announces Positive Interim Results of a First-in-Man Clinical Trial With Medusa(TM) Exenatide

Marketwired December 22, 2015

Flamel Technologies Appoints Michael Kanan Chief Financial Officer

Marketwired November 23, 2015

Flamel Technologies Reports Third Quarter 2015 Results

Marketwired November 12, 2015

Flamel Technologies to Report Third Quarter 2015 Results

Marketwired October 26, 2015

Flamel Ireland Limited Licenses LiquiTime(R) Technology to Perrigo for U.S. Over-the-Counter Market

Marketwired October 5, 2015

Perrigo and Flamel Enter Into Exclusive Licensing Agreement for LiquiTime® Extended Release Suspension Technology in the U.S. OTC Market

PR Newswire October 5, 2015

Flamel Technologies to Present at Ladenburg Thalmann 2015 Healthcare Conference

Marketwired September 15, 2015

Flamel Technologies Announces FDA Acceptance of Third NDA Filing

Marketwired September 9, 2015

Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015

Marketwired July 30, 2015

Flamel Technologies Announces Results of 2015 Annual Meeting; Domestic U.S. Public Company Reporting Status to Begin in 2016

Marketwired July 22, 2015

Flamel Technologies Announces Results of 2015 Annual Meeting; Domestic U.S. Public Company Reporting Status to Begin in 2016

Marketwired July 22, 2015

Flamel Technologies to Report Second Quarter of Fiscal Year 2015 Results

Marketwired July 20, 2015

Flamel Technologies to Report Second Quarter of Fiscal Year 2015 Results

Marketwired July 20, 2015